Pds biotech announces oral presentation of pds0101 data by the national cancer institute at 2021 american society of clinical oncology annual meeting

Florham park, n.j., april 29, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, today announced that initial efficacy and safety data from the national cancer institute's (nci) phase 2 clinical study of pds0101 for the treatment of advanced human papillomavirus (hpv)-associated cancers that have progressed or returned after treatment (nct04287868) has been accepted for oral presentation at the american society of clinical oncology (asco) 2021 annual meeting taking place june 4-8.
PDSB Ratings Summary
PDSB Quant Ranking